We are live on !
Find out more
PAP
Persistent Asset Partners Portfolio holdings
AUM
$335M
Turnover
79.96%
1-Year Est. Return
275.57%
This Fund
S&P 500
This Quarter Est. Return
+61.37%
1 Year Est. Return
+275.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$335M
AUM Growth
+$66.9M
(+25%)
Cap. Flow
-$37.3M
Cap. Flow % of AUM
Cap. Flow %
-11.13%
Top 10 Holdings %
Top 10 Hldgs %
34.76%
Holding
938
New
616
Increased
74
Reduced
90
Closed
134
Avg Time Held
Equity + Options
0.1
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.1
years
Avg Time Held Equity only
0.1
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Robinhood
HOOD
|
+$16M |
| 2 |
STMicroelectronics
STM
|
+$13.6M |
| 3 |
Amphenol
APH
|
+$10.9M |
| 4 |
Seagate
STX
|
+$7.07M |
| 5 |
Ford
F
|
+$6.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sandisk
SNDK
|
+$18.4M |
| 2 |
Lumentum
LITE
|
+$14.5M |
| 3 |
AXT Inc
AXTI
|
+$13.3M |
| 4 |
Tower Semiconductor
TSEM
|
+$11.9M |
| 5 |
Micron Technology
MU
|
+$10.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 38.35% |
| 2 | Healthcare | 29.66% |
| 3 | Financials | 6.33% |
| 4 | Miscellaneous | 6.14% |
| 5 | Consumer Discretionary | 5.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Invesco S&P 500 Low Volatility ETF
SPLV
$7.13B
| $575K | 0.17% |
+7,680
| New | +$566K |
2026 Q2
0 quarters
|
|
102
ArriVent BioPharma
AVBP
$885M
| $547K | 0.16% |
15,734
+7,626
| +94% | +$225K |
2025 Q4
2 quarters
|
|
103
Dianthus Therapeutics
DNTH
$4.17B
| $543K | 0.16% |
5,571
-1,871
| -25% | -$163K |
2025 Q4
2 quarters
|
|
104
Contineum Therapeutics
CTNM
$280M
| $541K | 0.16% |
+33,037
| New | +$433K |
2026 Q2
0 quarters
|
|
105
Repligen
RGEN
$11.2B
| $532K | 0.16% |
+3,902
| New | +$479K |
2026 Q2
0 quarters
|
|
106
Nokia
NOK
$50.8B
| $523K | 0.16% |
+39,402
| New | +$507K |
2026 Q2
0 quarters
|
|
107
Nektar Therapeutics
NKTR
$1.25B
| $522K | 0.16% |
7,481
+1,661
| +29% | +$122K |
2026 Q1
1 quarter
|
|
108
CALL
Summit Therapeutics
SMMT
$12.4B
| $520K | 0.16% |
+2,194
| New | +$38.9K |
2026 Q2
0 quarters
|
|
109
Phathom Pharmaceuticals
PHAT
$567M
| $517K | 0.15% |
47,663
+20,897
| +78% | +$238K |
2025 Q4
2 quarters
|
|
110
Mirum Pharmaceuticals
MIRM
$5.34B
| $516K | 0.15% |
4,404
+824
| +23% | +$82.7K |
2025 Q4
2 quarters
|
|
111
Almonty Industries
ALM
$2.55B
| $509K | 0.15% |
+30,733
| New | +$586K |
2026 Q2
0 quarters
|
|
112
Bicycle Therapeutics
BCYC
$248M
| $497K | 0.15% |
117,254
-3,183
| -3% | -$14.6K |
2026 Q1
1 quarter
|
|
113
Alkermes
ALKS
$7.21B
| $489K | 0.15% |
9,338
-16,225
| -63% | -$634K |
2026 Q1
1 quarter
|
|
114
Fulgent Genetics
FLGT
$553M
| $488K | 0.15% |
+23,793
| New | +$403K |
2026 Q2
0 quarters
|
|
115
CALL
Tenax Therapeutics
TENX
$56.9M
| $481K | 0.14% |
+782
| New | +$10K |
2026 Q2
0 quarters
|
|
116
Liquidia Corp
LQDA
$3.05B
| $479K | 0.14% |
+6,005
| New | +$322K |
2026 Q2
0 quarters
|
|
117
Enliven Therapeutics
ELVN
$2.84B
| $479K | 0.14% |
9,433
+2,827
| +43% | +$120K |
2026 Q1
1 quarter
|
|
118
Trevi Therapeutics
TRVI
$1.7B
| $477K | 0.14% |
25,601
-2,312
| -8% | -$33.6K |
2025 Q1
5 quarters
|
|
119
Veradermics Inc
MANE
$5.11B
| $469K | 0.14% |
3,811
-5,380
| -59% | -$504K |
2026 Q1
1 quarter
|
|
120
Viridian Therapeutics
VRDN
$2.36B
| $468K | 0.14% |
+25,490
| New | +$411K |
2026 Q2
0 quarters
|
|
121
Cytokinetics
CYTK
$8.71B
| $455K | 0.14% |
+5,346
| New | +$384K |
2026 Q2
0 quarters
|
|
122
Avalo Therapeutics
AVTX
$622M
| $454K | 0.14% |
24,544
+16,626
| +210% | +$263K |
2025 Q4
2 quarters
|
|
123
CALL
Alumis Inc
ALMS
$821M
| $444K | 0.13% |
508
+255
| +101% | +$5.93K |
2026 Q1
1 quarter
|
|
124
News Corp Class B
NWS
$17.7B
| $444K | 0.13% |
15,810
-17,866
| -53% | -$531K |
2025 Q3
3 quarters
|
|
125
MacroGenics
MGNX
$212M
| $441K | 0.13% |
95,371
-56,357
| -37% | -$213K |
2026 Q1
1 quarter
|
|
Similar funds
JWM
PI
TFA
SIM
OWM
SS
BIA
TODC
Persistent Asset Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Persistent Asset Partners held 938 positions worth $335M, up 25% from $268M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Persistent Asset Partners withdrew a net $37.3M in Q2 2026, closing 134 positions and reducing 90 holdings. Its most notable exit was Lumentum, an estimated $14.5M position sold in full.
By sector, the portfolio is most concentrated in Technology at 38% of assets, down from 45% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Persistent Asset Partners opened a new position in Robinhood worth $19.2M.
- Persistent Asset Partners's largest Q2 2026 buy was Robinhood: 191,095 shares worth $19.2M.
- Persistent Asset Partners added most to United Therapeutics in Q2 2026, an estimated $3.99M increase.
- Persistent Asset Partners's biggest Q2 2026 reduction was Sandisk, cutting an estimated $18.4M.
- Persistent Asset Partners fully exited Lumentum in Q2 2026, selling an estimated $14.5M.
- Persistent Asset Partners's ten largest holdings make up 35% of its $335M portfolio in Q2 2026.
- Persistent Asset Partners opened 616 new positions and closed 134 in Q2 2026.
- Persistent Asset Partners's portfolio value rose 25% quarter-over-quarter to $335M.
Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.